Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II

NCT07686926 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Becotatug Vedotin
DRUG: Tislelizumab
DRUG: Lenvatinib

Sponsor

Tianjin Medical University Cancer Institute and Hospital